Pramlintide
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 258
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.